Secukinumab Completed Phase 4 Trials for Psoriasis (PsO) Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science4
clinicaltrials.gov IdentifierTitleDrugs
NCT02592018Immunologic Response to Secukinumab in Plaque Psoriasis